Details of the Drug

General Information of Drug (ID: DM4L59B)

Drug Name
Teprotumumab
Synonyms RV001
Indication
Disease Entry ICD 11 Status REF
Graves disease 5A02.0 Approved [1]
Diabetic macular edema 9B71.02 Phase 1 [2]
Affected Organisms
Humans
ATC Code
L04AA53: Teprotumumab
L04AA: Selective immunosuppressants
L04A: IMMUNOSUPPRESSANTS
L04: IMMUNOSUPPRESSANTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 138000 +/- 34 mgh/L [3]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 632 +/- 139 mg/L [3]
Clearance
The clearance of drug is 0.27 L/day [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 20 +/- 5 days [3]
Vd
The volume of distribution (Vd) of drug is 3.26 +/- 0.87 L [3]
Cross-matching ID
UNII
Y64GQ0KC0A
DrugBank ID
DB06343
TTD ID
D0EN0W
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Insulin-like growth factor I receptor (IGF1R) TTHRID2 IGF1R_HUMAN Antagonist [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Graves disease
ICD Disease Classification 5A02.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Insulin-like growth factor I receptor (IGF1R) DTT IGF1R 1.64E-01 0.25 0.64
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 FDA Approved Drug Products: Tepezza (teprotumumab-trbw) for intravenous injection